Adagio Medical Holdings Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
4.3%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$1.09next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
FULCRUM-VT Trial Enrollment Quarterly209.0Target: 209 (Fully Enrolled)
Freedom from ICD Shock at 6 Months (FULCRUM-VT) Annually0.8Target: 84.3% freedom from ICD shock
Protocol-defined Major Adverse Events Rate (FULCRUM-VT) Annually2.4%Target: 2.4% major adverse events rate
Watch Items
- FDA PMA Submission for vCLAS Cryoablation SystemTrigger: Submission completionAction: Monitor regulatory filings and FDA feedback regarding the PMA application.
- vCLAS Ultra System IDE Trial ExpansionTrigger: First patient treated with next-generation systemAction: Track clinical progress and safety profile of the next-generation vCLAS Ultra catheter.
- Cash Runway and Additional FinancingTrigger: Cash reserves falling below $10 millionAction: Evaluate potential dilution from warrant exercises or new equity/debt financing rounds.
Research as of 20 Jun 2026